Wearable TENS Device Cleared for Fibromyalgia Treatment
The Quell neuromodulation device has received the FDA De Novo authorization for use as an aid in reducing the symptoms of fibromyalgia.
The Quell neuromodulation device has received the FDA De Novo authorization for use as an aid in reducing the symptoms of fibromyalgia.
The 2016 guideline issues by the CDC likely contributed to a substantial decrease in the intensity of opioid prescriptions for chronic pain.
Fifteen treatments with active tDCS were superior to sham tDCS only with regards to depression and anxiety in fibromyalgia.
Researchers assessed the role of ultrasonography in the evaluation of disease activity in patients with psoriatic arthritis with concomitant fibromyalgia syndrome.
The phase 3 RALLY study is evaluating the efficacy and safety of TNX-102 SL in 514 adult patients with fibromyalgia.
Researchers evaluated the association between Assessment of Spondyloarthritis International Society Health Index (ASAS-HI) and disease activity and burden in patients with spondyloarthritis.
The researchers’ goal was to provide the initial evidence for the safety and efficacy of sublingual ketamine in patients with chronic nonmalignant pain.
The researcher’s goal was to compare the impact of symptoms, along with health care utilization of those diagnosed with fibromyalgia, those who fulfill the criteria but are undiagnosed, and those with chronic pain.
A team of researchers conducted a genome-wide association study to gain insight into the genetics of chronic widespread pain
The researchers compared well-being and feelings of stigmatization in people with well understood conditions and in those with less understood condition, fibromyalgia, using daily diaries.